| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma (NCT05326243) | Pell Bio-Med Technology Co., Ltd. | 2022-05-31 |
| Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (NCT04759586) | National Cancer Institute (NCI) | 2021-10-05 |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy (NCT05075603) | NeoImmuneTech | 2021-07-29 |
| Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL) (NCT04824950) | Centre Henri Becquerel | 2021-03-22 |
| RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies (NCT04844086) | Eden BioCell Ltd. | 2021-03-02 |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T (NCT04488354) | Calibr, a division of Scripps Research | 2021-01-21 |
| Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL (NCT04705129) | Ruijin Hospital | 2021-01-01 |
| Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity (NCT04503538) | Wake Forest University Health Sciences | 2020-12-01 |
| Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma (NCT04231877) | University of Washington | 2020-10-27 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (NCT04545762) | C. Babis Andreadis | 2020-09-11 |
| Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) (NCT04542824) | Genmab | 2020-08-20 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (NCT04450069) | Calibr, a division of Scripps Research | 2020-08-14 |
| 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers (NCT04464200) | Memorial Sloan Kettering Cancer Center | 2020-07-06 |
| TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT04323657) | TCR2 Therapeutics | 2020-03-27 |
| LITT and Pembrolizumab in Recurrent Brain Metastasis (NCT04187872) | University of Florida | 2020-01-10 |
| Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma (NCT04833504) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2018-09-22 |
| Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma (NCT04067414) | Institute of Hematology & Blood Diseases Hospital, China | 2018-06-08 |
| Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs (NCT03346642) | Chinese PLA General Hospital | 2017-05-01 |
| Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT02653989) | Medivation, Inc. | 2016-12-01 |
| Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma (NCT01965119) | Samsung Medical Center | 2013-11-15 |
| A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL (NCT02423291) | Fondazione Italiana Linfomi - ETS | 2013-10-01 |
| Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL (NCT01897571) | Epizyme, Inc. | 2013-06-13 |
| Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation (NCT01516567) | Gustave Roussy, Cancer Campus, Grand Paris | 2012-04-01 |
| CT-011 MAb in DLBCL Patients Following ASCT (NCT00532259) | CureTech Ltd | 2007-10-01 |
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (NCT00001337) | National Cancer Institute (NCI) | 1993-05-08 |